Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.95
    -0.41 (-0.49%)
     

  • GOLD FUTURES

    2,334.80
    -7.30 (-0.31%)
     

  • DOW

    38,491.55
    -12.14 (-0.03%)
     

  • Bitcoin GBP

    51,636.45
    -1,760.40 (-3.30%)
     

  • CMC Crypto 200

    1,390.33
    -33.77 (-2.37%)
     

  • NASDAQ Composite

    15,715.42
    +18.78 (+0.12%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Update on Bausch & Lomb’s Top Products since 4Q17

Daniel Collins
Updated
Update on Bausch & Lomb’s Top Products since 4Q17

In 4Q17, Soflens, a product of Valeant Pharmaceuticals International’s (VRX) subsidiary Bausch & Lomb, reported revenues of $78 million compared to $79 million in 4Q16. That was a 1% decline on a YoY (year-over-year) basis and a 6% decline quarter-over-quarter.

Continue reading